Alpex Acquisition Corporation — Form 10-Q Summary
Reporting period: Quarter ended September 30, 2026. The Cayman Islands SPAC was incorporated January 5, 2026, completed its IPO on June 26, 2026, and had not completed a business combination or generated operating revenue by quarter-end. No comparable 2025 period exists.
Financial position and results
- Revenue and profit: No operating revenue. Third-quarter net income was $924,086, comprising $1,042,157 of interest and investment income less $118,072 of operating expenses. Trust-account income contributed $1,038,267. Inception-to-date net income was $676,441 on $399,357 of operating expenses. Earnings primarily reflect restricted trust investment income, not operating performance.
- Per-share results: Basic and diluted net income per share was $0.06 for the quarter and $0.10 from inception through September 30, 2026.
- Cash and liquidity: Cash outside the trust was $282,656; prepaid expenses were $466,781, including $291,781 of prepaid financial-advisory services. The trust account held $116,070,637, generally unavailable for ordinary expenses.
- Cash flow: Inception-to-date operating cash used was $691,026; investing cash used was $115.0 million, principally for initial trust funding; financing cash provided was $115,973,682. Ending unrestricted cash was $282,656.
- Liabilities and equity: Current liabilities were $226,653, including a $209,653 non-interest-bearing Sponsor promissory note and $17,000 of accrued expenses. The company also had an $805,000 deferred underwriting fee payable upon completion of a business combination. Shareholders’ deficit was $282,216.
- Margins and debt: Operating margins are not meaningful because the company has no operating revenue. The filing reports the Sponsor note but no conventional interest-bearing debt; no working capital loans were outstanding.
Material changes and notable items
- The IPO raised $115.0 million, and the Sponsor’s private placement generated $1.8 million in cash plus a $75,000 offset against Sponsor advances. The full over-allotment was exercised.
- During the quarter, the company paid $300,000 for financial-advisory services and $75,000 as an initial legal-engagement payment; unconsumed amounts are included in prepaid expenses. It recognized $8,219 of advisory expense for September 21–30.
- The $1,038,267 increase in redeemable public shares’ carrying value was recorded in equity, not net income. The $64,401 director share-based compensation was noncash and recognized from inception through September 30.
- In November 2026, the company entered a non-binding letter of intent with a prospective target. It remains subject to due diligence, definitive agreements and approvals; completion is not assured and the financial effect cannot yet be estimated.
Outlook, risks and controls
- The company must complete a business combination by June 26, 2027, unless validly extended. If it does not, it expects to cease operations, redeem public shares from the trust subject to applicable deductions and liquidate.
- Management concluded that substantial doubt exists about the company’s ability to continue as a going concern for one year after issuance. Trust funds are generally restricted, available operating cash is limited, and potential Sponsor or third-party financing is not assured. Management’s plans do not alleviate the substantial doubt.
- The filing provides no earnings or transaction-completion guidance. Management expects continuing transaction, advisory, legal and public-company costs.
- Disclosure controls and procedures were concluded to be ineffective as of September 30, 2026. No material change in internal control over financial reporting was reported during the quarter.
- No material legal proceedings were reported, and the company disclosed no material changes to the IPO prospectus risk factors.
Important facts for investors to verify
- Whether the non-binding target discussions progress to definitive agreements and required approvals.
- The available unrestricted cash, expected transaction-related spending and any committed financing as the June 26, 2027 deadline approaches.
- The going-concern uncertainty, Sponsor note, deferred underwriting fee and potential additional advisory and legal payments.
- Management’s remediation of ineffective disclosure controls and procedures.
- The terms of any deadline extension and the resulting redemption, liquidation and security-holder outcomes.